Neisseria meningitidis oligosaccharide conjugated to corynebacterium diphtheriae crm197
As of the edition of 20 October 2026, Neisseria meningitidis oligosaccharide conjugated to corynebacterium diphtheriae crm197 is a vaccine component: marketed, first approved in 2010 (US); US protection ended in 2022.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2010
- Kind
- Vaccine component
- Brand name
- Menveo
- First approved
- 19 February 2010 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- GSK
- Registered trials
- 34, 0 stopped early
- Disease areas
- Infections; Nervous system; Blood and lymph; Digestive system; Immune system; Lungs and airways
US protection
US protection ended in 2022.
US protection ended in 2022, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by GSK. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 3 | 0 | 0 |
| Phase 2 | 11 | 11 | 0 | 0 |
| Phase 3 | 13 | 13 | 0 | 0 |
| Phase 4 | 6 | 5 | 0 | 0 |
| All trials | 34 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Novartis | Lead sponsor of trials | 2005 to now |